FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百奧賽圖(北京)醫藥科技股份有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 688796 | 說明 | | 於上海證券交易所科創板上市之本公司A股 | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 336,116,500 | RMB | | 1 RMB | | 336,116,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 336,116,500 | RMB | | 1 RMB | | 336,116,500 | ...

Consumer Sector - During the Spring Festival of 2026, the average daily revenue from national catering consumption increased by 31.2%, significantly surpassing the overall consumption growth rate of 13.7%[4] - The average daily sales of key retail and catering enterprises monitored by the Ministry of Commerce grew by 5.7%, accelerating by 1.6 percentage points compared to 2025[4] - In terms of consumption types, the growth rate for dining services was 26.5%, while snack services experienced explosive growth of 42.1%[7] Hard Technology - Global capital expenditure by the eight major cloud service providers (CSPs) is expected to exceed $710 billion in 2026, representing a year-on-year growth of approximately 61%[13] - Google's self-developed TPU chips are projected to account for nearly 78% of its AI server shipments in 2026, widening the gap with GPUs[14] - The global Datacom CPO market is expected to grow from less than $70 million in 2024 to $8 billion by 2030, with a compound annual growth rate exceeding 120%[18] Health Sector - AI drug discovery can reduce the time and cost of drug development by up to 50% during preclinical and clinical stages[23] - The global AI pharmaceutical market is projected to reach $15.6 billion by 2025, with a compound annual growth rate of 25.7% from 2025 to 2030[24] - Companies with AI model development capabilities, such as InSilico Medicine and CrystalGenomics, are recommended for investment[26]

Investment Rating - The report maintains a "Buy" rating for the company [4][10]. Core Insights - The company achieved a revenue of 1.379 billion RMB in 2025, representing a year-on-year growth of 40.63%. The net profit attributable to shareholders was 173 million RMB, with a remarkable growth of 416.37% [10]. - The growth was driven by both domestic recovery and overseas expansion, with significant contributions from the model animals and preclinical CRO services [10]. - The antibody development segment is progressing well, with numerous collaborations that are expected to enhance future growth potential [10]. Financial Forecasts - Revenue projections for 2025-2027 are as follows: 1.379 billion RMB (2025), 1.849 billion RMB (2026), and 2.422 billion RMB (2027), with growth rates of 40.6%, 34.1%, and 31.0% respectively [3][11]. - Net profit forecasts for the same period are: 173 million RMB (2025), 335 million RMB (2026), and 528 million RMB (2027), with growth rates of 416.4%, 93.3%, and 57.7% respectively [3][11]. - The earnings per share (EPS) are projected to be 0.39 RMB (2025), 0.75 RMB (2026), and 1.18 RMB (2027) [3][11]. Business Segments - The model animals segment saw a revenue of 274 million RMB in the first half of 2025, growing by 56.13%, while preclinical CRO services generated 155 million RMB, marking a 90.10% increase [10]. - The company launched over 400 humanized mouse models in 2025, reinforcing its leading position in the humanized animal model market [10]. - The preclinical CRO services are experiencing rapid growth, particularly in pharmacology and efficacy research, with significant increases in various service areas [10]. Collaborations and Partnerships - As of the first half of 2025, the company signed approximately 280 drug collaboration agreements with around 120 pharmaceutical companies, including 80 new agreements in the first half of 2025 [10]. - A notable collaboration involves the ADC candidate IDE034, which has entered Phase I clinical trials, with potential milestone payments of up to 406.5 million USD [10].

Core Insights - Biocytogen Pharmaceuticals has announced that its partner IDEAYA Biosciences has initiated the first patient dosing in a Phase 1 clinical trial for IDE034, a bispecific antibody-drug conjugate targeting B7H3/PTK7 [1] Company Summary - Biocytogen Pharmaceuticals is a global biotechnology company focused on the research and development of novel antibody-based drugs utilizing innovative technologies [1] - IDEAYA Biosciences, a partner of Biocytogen, is conducting the clinical trial for IDE034, which is currently in the dose-escalation and expansion phase [1]

Core Viewpoint - The company Bai Aosaitu-B (02315) has experienced a significant stock price increase of over 5%, attributed to strong financial performance and ongoing expansion in overseas markets [1] Financial Performance - For the fiscal year 2025, the company expects to achieve a revenue of approximately 1.379 billion RMB, representing a year-on-year growth of 40.63% [1] - The net profit attributable to the owners of the company is projected to be 173 million RMB, reflecting a remarkable year-on-year increase of 416.37% [1] - The net profit after deducting non-recurring gains and losses is anticipated to be 116 million RMB, with a year-on-year growth of 405.39% [1] Asset and Equity Growth - The total assets of the company are expected to reach 3.724 billion RMB, an increase of 54.20% compared to the beginning of the period [1] - The equity attributable to the owners of the company is projected to be 2.175 billion RMB, showing a substantial increase of 160.76% from the start of the period [1] Strategic Drivers - The growth in operating performance is primarily driven by the continuous expansion into overseas markets, alongside a recovery in the domestic biopharmaceutical industry [1] - The company emphasizes an innovation-driven strategy, maintaining high levels of research and development investment to build core technological barriers and ensure stable high gross margins [1] - Lean management practices are being implemented to continuously enhance operational efficiency, contributing to rapid improvements in profitability [1]

Core Viewpoint - The company BaiO Saite-B (02315) has reported significant growth in its 2025 performance forecast, with a notable increase in revenue and net profit, driven by overseas market expansion and recovery in the domestic biopharmaceutical industry [1] Financial Performance - The expected revenue for 2025 is approximately 1.379 billion RMB, representing a year-on-year growth of 40.63% [1] - The net profit attributable to the company's owners is projected to be 173 million RMB, showing a substantial year-on-year increase of 416.37% [1] - The net profit attributable to the company's owners, excluding non-recurring gains and losses, is expected to be 116 million RMB, reflecting a year-on-year growth of 405.39% [1] Asset and Equity Growth - Total assets are anticipated to reach 3.724 billion RMB, an increase of 54.20% compared to the beginning of the period [1] - Equity attributable to the company's owners is projected to be 2.175 billion RMB, marking a significant increase of 160.76% from the beginning of the period [1] Strategic Drivers - The growth in operating performance is primarily attributed to the continuous expansion in overseas markets and the recovery of the domestic biopharmaceutical sector [1] - The company emphasizes an innovation-driven strategy, with sustained high-intensity R&D investment to build core technological barriers, ensuring stable high gross margins [1] - Lean management practices are being implemented to continuously enhance operational efficiency, contributing to rapid improvements in profitability [1]

Core Viewpoint - Baosai Technology-B (02315) has seen a stock price increase of over 5%, currently trading at 55.75 HKD, with a transaction volume of 6.6351 million HKD [1] Financial Performance - For the fiscal year 2025, the company expects a revenue of approximately 1.379 billion RMB, representing a year-on-year growth of 40.63% [1] - The net profit attributable to the owners of the company is projected to be 173 million RMB, showing a significant year-on-year increase of 416.37% [1] - The net profit attributable to the owners of the company, excluding non-recurring gains and losses, is expected to be 116 million RMB, reflecting a year-on-year growth of 405.39% [1] - Total assets of the company are estimated to be 3.724 billion RMB, an increase of 54.20% compared to the beginning of the period [1] - Equity attributable to the owners of the company is projected to be 2.175 billion RMB, which is a substantial increase of 160.76% from the beginning of the period [1] Growth Drivers - The growth in operating performance is primarily attributed to the continuous expansion in overseas markets, coupled with the recovery of the domestic biopharmaceutical industry [1] - The company maintains a strategy of driving performance growth through innovation, supported by sustained high-intensity R&D investments to build core technological barriers [1] - Lean management practices are being implemented to continuously enhance operational efficiency, thereby rapidly improving the company's profitability [1]

Core Viewpoint - The company Baiaosaitu-B (02315) is expected to report significant growth in its 2025 fiscal year, with a projected revenue of approximately 1.379 billion RMB, representing a year-on-year increase of 40.63% [1] Financial Performance - The net profit attributable to the company's owners is projected to be 173 million RMB, showing a remarkable year-on-year growth of 416.37% [1] - The net profit attributable to the company's owners, excluding non-recurring gains and losses, is expected to be 116 million RMB, reflecting a year-on-year increase of 405.39% [1] - Total assets of the group are anticipated to reach 3.724 billion RMB, an increase of 54.20% compared to the beginning of the period [1] - The equity attributable to the company's owners is projected to be 2.175 billion RMB, which is a significant increase of 160.76% from the beginning of the period [1] Growth Drivers - The growth in the company's operating performance is primarily attributed to the continuous expansion in overseas markets, coupled with the recovery of the domestic biopharmaceutical industry [1] - The company maintains a strategy of driving performance growth through innovation, supported by sustained high-intensity R&D investment to build core technological barriers [1] - Lean management practices are being implemented to continuously enhance operational efficiency, which contributes to the rapid improvement of the company's profitability [1]

Core Viewpoint - The company reported significant growth in revenue and net profit for the fiscal year 2025, driven by overseas market expansion and recovery in the domestic biopharmaceutical industry [1] Financial Performance - The company achieved operating revenue of RMB 1.379 billion, representing a year-on-year increase of 40.63% [1] - The net profit attributable to the owners of the company was RMB 173 million [1] - The net profit attributable to the owners of the company, excluding non-recurring gains and losses, was RMB 116 million [1] Strategic Initiatives - The company's growth was supported by a strategy focused on innovation, with sustained high levels of R&D investment to build core technological barriers [1] - The company emphasized lean management to continuously improve operational efficiency, contributing to rapid enhancement of profitability [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 內幕消息 2025年度業績快報公告 本公告由百奧賽圖（北京）醫藥科技股份有限公司（「本公司」，連同其附屬公司 統稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)(a)條及第 13.10B條項下披露責任以及證券及期貨條例（香港法例第571章）第XIVA部項下的 內幕消息條文作出。 本公司於本公告載列2025年度財務數據，數據乃根據《中國企業會計準則》編製， 且僅為初步會計數據，未經註冊會計師審計。本公告所載數據與本公司2025年年 度報告所披露的最終數據或有區別。本公司股東及投資者在買賣本公司股份時務 請審慎行事。 一、 2025年度主要財務數據和指標 1 | | 本報告期末 | 本報告 ...